Market Access News | pharmaphorum

News

FDA turns down Lilly’s eczema drug lebrikizumab

Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop

News

WHO clears Oxford malaria jab for immunisation programmes

The World Health Organization (WHO) has recommended the use of a malaria vaccine developed at Oxford University in the UK, after concluding it is 75% effective at protecti

News

Biogen claims first with FDA nod for biosimilar Actemra

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra.

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

Pharma says EU chemical ban could devastate manufacturing

A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind

News

MSD eyes March FDA decision on PAH drug sotatercept

MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by

FDA turns down Lilly’s eczema drug lebrikizumab

WHO clears Oxford malaria jab for immunisation programmes

Biogen claims first with FDA nod for biosimilar Actemra

FDA starts swift review of Regeneron’s CD20 bispecific

Pharma says EU chemical ban could devastate manufacturing

MSD eyes March FDA decision on PAH drug sotatercept

Is J&J approaching the end of its talc litigation hangover?

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks